The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation

Background: Anti-EGFR therapies have been recommended for advanced colorectal cancer (CRC) with wild-type RAS and PIK3CA mutation. However, PIK3CA mutations are a poor prognostic marker and a negative predictor of response to anti-EGFR therapies in RAS wild-type CRC. Therefore, new and advanced trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ju Sun, Kim, Jung Eun, Kim, Kyung, Lee, Jeeyun, Park, Joon Oh, Lim, Ho Yeong, Park, Young Suk, Kang, Won Ki, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604203/
https://www.ncbi.nlm.nih.gov/pubmed/28928860
http://dx.doi.org/10.7150/jca.19458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604203/
https://www.ncbi.nlm.nih.gov/pubmed/28928860
http://dx.doi.org/10.7150/jca.19458

Ejemplares similares